## Gene Summary
F3, also known as tissue factor or thromboplastin, plays a critical role in the blood coagulation cascade functioning primarily as a cellular receptor for factor VIIa. The binding of factor VIIa to F3 initiates the conversion of factor X to Xa and factor IX to IXa, eventual culminations in thrombin formation, and blood clot formation. F3 is expressed in various tissues including the brain, lungs, and placenta, but is most prominently expressed in the sub-endothelial cells and leukocytes, where its expression can be induced by inflammatory cytokines.

## Gene Drugs, Diseases, Phenotypes, and Pathways
F3 is a key player in hemostasis and thus is implicated in various bleeding disorders when dysfunctional. Aberrant expression or function of F3 has been linked to an increased risk of thrombosis, leading to conditions such as deep vein thrombosis, myocardial infarction, and stroke. F3's prominent role in thrombosis also makes it a target for anticoagulant drugs. Besides, F3 is involved in multiple biochemical pathways, including the intrinsic and extrinsic coagulation cascades and the signal transduction pathways that mediate cellular responses to tissue injury.

## Pharmacogenetics
From a pharmacogenetic perspective, variations in the F3 gene are of interest due to their influence on the treatment of thrombotic conditions. Certain polymorphisms in the F3 gene have been associated with altered risk and severity of thrombotic events, which can influence the dosage and choice of anticoagulant drugs for individual patients. Drugs such as warfarin and heparin, which are used to manage thrombosis and coagulation disorders, might be affected by F3 variants in terms of their pharmacodynamics and efficacy. Understanding these genetic variations can help tailor anticoagulant therapies more effectively to reduce the risk of excessive bleeding or inadequate clot prevention.